

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Proteomics International Laboratories Ltd</b>
<b>ABN</b>	<b>78 169 979 971</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Richard Lipscombe
<b>Date of last notice</b>	28 September 2020

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Not applicable
<b>Date of change</b>	23 January 2024
<b>No. of securities held prior to change</b>	<i>Direct</i> 9,162,115 fully paid ordinary shares <b>(Shares)</b>  <i>Indirect</i> 9,886,590 Shares
<b>Class</b>	Shares
<b>Number acquired</b>	Not applicable
<b>Number disposed</b>	2,631,579 Shares.
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$2,000,000 (\$0.76 per Share).

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>No. of securities held after change</b>	<i>Direct</i> 6,530,536 Shares  <i>Indirect</i> 9,886,590 Shares
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Sale by block trade concurrent with the placement to facilitate institutional investor participation without additional equity dilution. For further information regarding the institutional placement and sell-down refer to the ASX announcement dated 23 January 2024.

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Not applicable.
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	Yes
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	Yes

<sup>+</sup> See chapter 19 for defined terms.

If prior written clearance was provided, on what date was this provided?	22 January 2024
--	-----------------

---

+ See chapter 19 for defined terms.